Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Appointed director
Inv. presentation
Quarterly results
Appointed COO
|
|
TIANYIN PHARMACEUTICAL CO., INC. (TPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/05/2016 |
8-K
| Quarterly results |
| 04/07/2016 |
8-K
| Form 8-K - Current report |
| 03/02/2016 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 12/02/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , received notice on November 25, 2015 from the NYSE MKT LLC indicating that the Company is below certain of the Exchange’ s continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2015 , in addition to the delay in filing of its Annual Report on Form 10-K for the year ended June 30, 2015 . Under NYSE MKT rules, until the Company files the Form 10-Q and Form 10-K, its c..." |
|
| 10/19/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , received notice on October 16, 2015 from the NYSE MKT LLC indicating that the Company is below certain of the Exchange’ s continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Annual Report on Form 10-K for the year ended June 30, 2015 . Under NYSE MKT rules, until the Company files the Form 10-K, its common stock will remain listed on the NYSE MKT under the symbol “TPI,” but will be assigned an “.LF” indicator to signify late fi..." |
|
| 10/16/2015 |
8-K
| Other Events |
| 09/22/2015 |
8-K
| Other Events |
| 08/11/2015 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review |
| 07/17/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 07/14/2015 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets |
| 06/25/2015 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/22/2015 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 05/26/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to... |
| 02/26/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 01/28/2015 |
8-K
| Appointed a new director |
| 01/16/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"TPI to Form Strategic Alliance with Buchang Pharma CHENGDU, China, Jan. 14, 2015 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. , a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients today announced that TPI and Buchang Pharmaceutical Co., Ltd. plan to establish Tianyin-Buchang Strategic Alliance to synergize and accelerate the growth of the Company, boosting TPI's mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan . 1. The Alliance platform will be established based upon TPI's newly completed and GMP-certified Qionglai Tianyin Facility with the latest technologies and expanded production capacities in mTCM pre-extraction, purification and formulati..." |
|
| 01/06/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/21/2014 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , today reported that, on October 15, 2014, it received a notice from the NYSE MKT Staff indicating that the Company is below certain of the continued listing standards of the NYSE MKT as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing its Annual Report on Form 10-K for fiscal year ended June 30, 2014 beyond the extended filing due date of October 14, 2014. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will rem..." |
|
| 10/16/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/15/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 CHENGDU, China, Oct. 15, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , today reported that it has delayed the filing of its Annual Report on Form 10-K for the year ended June 30, 2014 beyond the extended filing due date of October 14, 2014. As TPI indicated in its Current Reports on Form 8-K filed on October 8, 2013 and November 4, 2013, its Audit Committee and the Board of Directors both unanimously approved the termination of the Company's independent auditor, Patrizio and Zhao LLC..." |
|
| 05/28/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/19/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/06/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 04/07/2014 |
8-K
| Other Events |
| 02/21/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 -- Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients announced financial results for the second quarter of fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31, 2013 Financial Highlights: ● Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of 21% year over year; ● Gross profit was $6.2 million with gross margin at 45% versus gross profit of $6.8 million with gross margin at 39% in the second quarter FY 2013; ● Operating income was $2.5 million, compared with $2.6 million in the ...",
"Script of Conference Call on February 14, 2014" |
|
| 11/20/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/04/2013 |
8-K
| Form 8-K - Current report |
| 10/08/2013 |
8-K
| Form 8-K - Current report |
| 10/02/2013 |
8-K
| Form 8-K - Current report |
| 05/20/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/13/2013 |
8-K
| Conference call transcript |
| 05/09/2013 |
8-K
| Form 8-K - Current report |
| 02/19/2013 |
8-K
| Form 8-K - Current report |
| 11/21/2012 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
|
|
|